PROCEPT BioRobotics is executing on a robust growth trajectory, with revenue expanding 19.3% year-over-year to $94.5M in 2026Q2, driven by record HYDROS placements and a favorable mix shift toward higher-margin disposables, which lifted gross margin to 66.0%.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.46-17.5% vs -$0.39 | $98M-2.2% vs $101M |
Q3 2026 Aug 4, 2026 | -$0.47-1.8% vs -$0.46 | $94M+1.9% vs $93M |
Q2 2026 Apr 29, 2026 | -$0.56-1.8% vs -$0.55 | $83M+3.2% vs $81M |
Q1 2026 Feb 25, 2026 | -$0.53-65.6% vs -$0.32 | $76M-18.5% vs $94M |
PROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements at new U.S. accounts.
PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.38 per share a year ago.
SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.
Benchmark PRCT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PROCEPT BioRobotics Corporation (PRCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.62 | $1.17B | -10.29 | 37.22% | -32.6% | -33.23% | — | |
| $452.80 | $159.96B | 53.84 | 20.51% | 25.54% | 16.91% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — | |
| $162.55 | $308.96B | 30.86 | 5.97% | 17.82% | 24.32% | 2.47% |
PROCEPT BioRobotics Corporation (PRCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PROCEPT BioRobotics Corporation (PRCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 10, 2026·SEC
Apr 29, 2026·SEC
Get notified when PRCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PROCEPT BioRobotics Corporation (PRCT) stock FAQ — growth, dividends, profitability & financials explained
PROCEPT BioRobotics Corporation (PRCT) reported $352.3M in revenue over the trailing twelve months. Revenue was $308.1M in fiscal year 2025. That is 4894% more than the $6.2M of fiscal year 2019.
PROCEPT BioRobotics Corporation (PRCT) grew revenue by 17.5% over the trailing twelve months, compared with the twelve months before.
No. PROCEPT BioRobotics Corporation (PRCT) reported a net loss of $114.9M over the trailing twelve months.
PROCEPT BioRobotics Corporation (PRCT) had a return on equity (ROE) of -33.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
PROCEPT BioRobotics Corporation (PRCT) had negative free cash flow of $126.1M over the trailing twelve months.
